| Ytd | -36.50% | |
| 1y | 18.24% |
| Open | 10.85 | Prev Close | 10.85 | Low | 10.42 | High | 11.01 | Mkt Cap | 840.23M |
| Vol | 901.34K | Avg Vol | 1.19M | EPS | -2.09 | P/E | N/A | Forward P/E | 7.60 |
| Beta | 0.61 | Short Ratio | 9.36 | Inst. Own | 83.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 11.16 | 200-d Avg | 12.70 | 1yr Est | 23.70 |
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and c
HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT)